Recommendations for the assessment of progression in randomised cancer treatment trials
European Journal of Cancer2008Vol. 45(2), pp. 281–289
Citations Over TimeTop 11% of 2008 papers
Janet Dancey, Lori E. Dodd, Robert Ford, Richard Kaplan, Margaret Mooney, Larry Rubinstein, Lawrence H. Schwartz, Lalitha Shankar, P. Therasse
Related Papers
- → Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer(2018)18 cited
- → Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials(2017)7 cited
- → Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma(2022)3 cited
- → Efficacy and Safety in Clinical Trials in Cardiovascular Disease(2006)14 cited
- → Progression-free survival, patient-reported outcomes, and the Holy Grail(2014)3 cited